^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

anti-CD22 CAR-T cell therapy

i
Other names: anti-CD22 CAR-T cell therapy, CD22 CAR-T cells
Associations
Trials
Company:
Shanghai Yake Biotech
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
1year
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. (PubMed, Lancet Oncol)
This sequential strategy induced deep and sustained responses with an acceptable toxicity profile, and thus potentially provides long-term benefits for children with this condition.
P2 data • Clinical Trial,Phase II • Journal • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD19/CD22 CAR-T cell therapy • anti-CD22 CAR-T cell therapy
1year
Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults (ASH 2023)
Dasatinib in combination with a two-week vincristine and glucocorticoids regimen were administered, followed by sequential infusions of CD19 and CD22 CAR-T cells. Conclusions Dasatinib in combination with CAR-T cell therapy has enabled chemotherapy-free treatment in newly diagnosed Ph-positive ALL. This treatment is characterized by high complete molecular response, high long-term survival, low toxicity and short treatment cycles.
Clinical • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)
|
BCR-ABL1 F317L • BCR-ABL1 Y253H • ABL1 F317L • ABL1 Y253H
|
dasatinib • vincristine • CD19/CD22 CAR-T cell therapy • anti-CD22 CAR-T cell therapy
4years
[VIRTUAL] CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma:a Safety and Efficacy Study (ASH 2020)
Conclusions Immunotherapy with a novel CD19/CD22 dual targeted CAR-T cells yields a potent and durable anti-lymphoma response with no neurotoxicity or severe CRS. Bispecific CD19/CD22 CAR-T cells represent a safe and potent anti-lymphoma cellular based targeted immunotherapy.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B)
|
CD19 expression
|
anti-CD22 CAR-T cell therapy